PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bimekizumab→

Bimekizumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1418205-77-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Humanised monoclonal antibodydual interleukin-17A and interleukin-17F inhibitor
Mechanism of action
Selectively binds and neutralises IL-17A and IL-17F, preventing their interaction with the IL-17 receptor complex and reducing downstream inflammatory signalling.
Indications / reported uses
  • Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • Treatment of active psoriatic arthritis in adults
  • Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation and active ankylosing spondylitis in adults; exact eligibility and indications are product- and jurisdiction-specific

Sources: US FDA prescribing information — BIMZELX · EMA EPAR — Bimzelx · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bimekizumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bimekizumab Permitted Daily Exposure (PDE) report (the Bimekizumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bimekizumab Occupational Exposure Limit (OEL) report (the Bimekizumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.